Treatment of Vitamin B3 Deficiency During Therapy with a Pellagra-Inducing Medication

Certain medications are known to precipitate pellagra — a clinical manifestation of vitamin B3 deficiency — in patients who require them for ongoing treatment of an underlying condition. Managing this deficiency requires considering both the presenting symptoms and the necessity of the responsible pharmacotherapy.

Clinical scenario

This protocol applies to patients who develop vitamin B3 deficiency while receiving a medication capable of inducing pellagra, such as isoniazid, azathioprine, ethionamide, or 6-mercaptopurine. The central clinical challenge is that the underlying disease may require uninterrupted pharmacotherapy, complicating straightforward management.

Treatment approach

Management centres on the role of the causative medication. The full protocol specifies the intervention — and the evidence-based alternative for patients in whom continuous pharmacotherapy cannot be suspended.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.24425/fmc.2021.138956

In the case of drug-induced pellagra, discontinuation of the preparation responsible for the symptoms usually leads to a significant improvement.

However, it is worth emphasizing that niacinamide treatment, without resignation of pharmacotherapy, might be effective.

This is of great importance when the underlying disease requires continuous, intensive treatment (e.g., with immunosuppressive drugs).

View source ↗